XML 99 R63.htm IDEA: XBRL DOCUMENT v3.22.4
Related-Party Transactions - Additional Information (Details)
$ in Thousands
1 Months Ended 12 Months Ended
Oct. 04, 2022
USD ($)
Jul. 01, 2020
Jul. 31, 2020
USD ($)
Jun. 30, 2018
Dec. 31, 2022
USD ($)
Investor
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Oct. 04, 2021
Related Party Transaction [Line Items]                
Related-party revenue         $ 0 $ 0 $ 1,182  
Research and development costs         $ 98,400 60,170 28,961  
ScalmiBio, Inc                
Related Party Transaction [Line Items]                
Research and development costs $ 600              
Business acquisition, percentage of voting interests acquired 31.70%             31.70%
Retention milestone payment $ 2,000              
Tallac Therapeutics | Lab Equipment and Other Assets                
Related Party Transaction [Line Items]                
Proceeds from transfer of assets     $ 600          
Research and Development Services Agreement | Tollnine                
Related Party Transaction [Line Items]                
Number of company's investors who are investors in related party as well | Investor         2      
Related-party revenue         $ 0 0 1,200  
Initial term of agreement with related party       3 years        
Markup cost in percentage       10.00%        
Research and Development Services Agreement | Tallac Therapeutics                
Related Party Transaction [Line Items]                
Initial term of agreement with related party   4 years            
Markup cost in percentage   10.00%            
Agreement automatically renewal additional term unless terminated   1 year            
Research and development costs         600 800 $ 600  
Collaboration Agreement | Tallac Therapeutics                
Related Party Transaction [Line Items]                
Research and development costs         7,800 2,800    
Accrued expenses due         $ 1,600 $ 1,400